Porcine Reproductive and Respiratory Syndrome Virus Engineered by Serine Substitution on the 44th Amino Acid of GP5 Resulted in a Potential Vaccine Candidate with the Ability to Produce High Levels of Neutralizing Antibody

Simple Summary The slow and weak formation of neutralizing antibodies against the PRRSV is related to the N-linked glycosylation site surrounding the major epitope in the ectodomain of GP5 protein. To develop vaccine candidates that induce high levels of neutralizing antibodies, various previous studies have attempted to substitute the various glycosylation sites with other amino acids. In this study, we created a new vaccine candidate, vCSL1-GP5-N44S, by replacing the 44th asparagine amino with serine. In an animal trial, piglets inoculated with vCSL1-GP5-N44S showed no adverse effects and had a protective efficacy, including a high level of neutralizing antibodies after the challenge. Therefore, it has been demonstrated that substituting the 44th N-linked glycosylation site of the GP5 protein with serine is preferable among the various substitution. Additionally, vCSL1-GP5-N44S has shown its potential as a vaccine candidate. Abstract N-linked glycans covering GP5 neutralizing epitopes of porcine reproductive and respiratory syndrome virus (PRRSV) have been proposed to act as a sheath blocking the production of neutralizing antibodies. Herein, we genetically engineered PRRSV with serine (S) substitution on the 44th asparagine (N) on the GP5 ectodomain of PRRSV-2 lineage-1. To evaluate the recombinant PRRSV, in vivo experiments were performed in piglets. The recombinant virus group showed no viremia until 42 days post-inoculation (dpi), and the rectal temperature and average daily weight gain were in the normal range at the same time point as the negative control group. On the 42 dpi, both groups were challenged with the wild-type virus. The recombinant PRRSV group showed lower rectal temperature, viremia, and the lung lesions than that of the negative control group for 19 days post-challenge (dpc). Additionally, the recombinant virus induced 4.50 ± 3.00 (log2) and 8.25 ± 0.96 (log2) of neutralizing antibody before and after challenge, respectively. Taken together, this study confirmed that N44S substitution can create an infectious PRRSV that strongly induces neutralizing antibodies. In addition, the vCSL1-GP5-N44S mutant that we produced was confirmed to have potential as a vaccine candidate, showing good safety and protective effects in pigs.

[1]  Wanglong Zheng,et al.  Minor and major envelope proteins of PRRSV play synergistic roles in inducing heterologous neutralizing antibodies and conferring cross protection. , 2022, Virus research.

[2]  Sang-Won Lee,et al.  Development of a Chimeric Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)-2 Vaccine Candidate Expressing Hypo-Glycosylated Glycoprotein-5 Ectodomain of Korean Lineage-1 Strain , 2022, Veterinary sciences.

[3]  M. Amadori,et al.  The Swine IFN System in Viral Infections: Major Advances and Translational Prospects , 2022, Pathogens.

[4]  N. Shabir,et al.  Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model , 2021, Vaccines.

[5]  Chang-Seon Song,et al.  A chimeric porcine reproductive and respiratory syndrome virus (PRRSV)-2 vaccine is safe under international guidelines and effective both in experimental and field conditions. , 2021, Research in veterinary science.

[6]  C. Nathues,et al.  Application of an economic calculator to determine the cost of porcine reproductive and respiratory syndrome at farm-level in 21 pig herds in Germany , 2021, Porcine Health Management.

[7]  Changhee Lee,et al.  Novel lineage 1 recombinants of porcine reproductive and respiratory syndrome virus isolated from vaccinated herds: genome sequences and cytokine production profiles , 2020, Archives of Virology.

[8]  M. Borca,et al.  A Single Amino Acid Substitution in the Matrix Protein (M51R) of Vesicular Stomatitis New Jersey Virus Impairs Replication in Cultured Porcine Macrophages and Results in Significant Attenuation in Pigs , 2020, Frontiers in Microbiology.

[9]  S. Cha,et al.  Field porcine reproductive and respiratory syndrome viruses (PRRSV) attenuated by codon pair deoptimization (CPD) in NSP1 protected pigs from heterologous challenge. , 2020, Virology.

[10]  Xuehui Cai,et al.  Adaptions of field PRRSVs in Marc-145 cells were determined by variations in the minor envelope proteins GP2a-GP3. , 2018, Veterinary microbiology.

[11]  Jienny Lee,et al.  Geographic distribution and molecular analysis of porcine reproductive and respiratory syndrome viruses circulating in swine farms in the Republic of Korea between 2013 and 2016 , 2018, BMC Veterinary Research.

[12]  F. Osorio,et al.  Development of a broadly protective modified-live virus vaccine candidate against porcine reproductive and respiratory syndrome virus. , 2018, Vaccine.

[13]  Jung-Ah Lee,et al.  In vitro and in vivo studies of deglycosylated chimeric porcine reproductive and respiratory syndrome virus as a vaccine candidate and its realistic revenue impact at commercial pig production level. , 2017, Vaccine.

[14]  Hiep L. X. Vu,et al.  Strategies to broaden the cross-protective efficacy of vaccines against porcine reproductive and respiratory syndrome virus. , 2017, Veterinary microbiology.

[15]  M. Murtaugh,et al.  Mechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome Virus , 2017, Viruses.

[16]  T. Opriessnig,et al.  An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs. , 2017, Vaccine.

[17]  T. Opriessnig,et al.  A porcine reproductive and respiratory syndrome virus candidate vaccine based on the synthetic attenuated virus engineering approach is attenuated and effective in protecting against homologous virus challenge. , 2016, Vaccine.

[18]  E. Mateu,et al.  Review on the transmission porcine reproductive and respiratory syndrome virus between pigs and farms and impact on vaccination , 2016, Veterinary Research.

[19]  N. Shabir,et al.  Evaluation of the Cross-Protective Efficacy of a Chimeric Porcine Reproductive and Respiratory Syndrome Virus Constructed Based on Two Field Strains , 2016, Viruses.

[20]  J. Lunney,et al.  Porcine Reproductive and Respiratory Syndrome Virus (PRRSV): Pathogenesis and Interaction with the Immune System. , 2016, Annual review of animal biosciences.

[21]  Chang-Seon Song,et al.  Augmented immune responses in pigs immunized with an inactivated porcine reproductive and respiratory syndrome virus containing the deglycosylated glycoprotein 5 under field conditions , 2016, Clinical and experimental vaccine research.

[22]  M. Murtaugh,et al.  Emergence of a virulent porcine reproductive and respiratory syndrome virus in vaccinated herds in the United States. , 2015, Virus research.

[23]  Fangrui Ma,et al.  A Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection , 2015, Journal of Virology.

[24]  C. Chae,et al.  Cross-protection of a new type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccine (Fostera PRRS) against heterologous type 1 PRRSV challenge in growing pigs. , 2015, Veterinary microbiology.

[25]  K. Faaberg,et al.  PRRSV structure, replication and recombination: Origin of phenotype and genotype diversity , 2015, Virology.

[26]  Sang-Won Lee,et al.  Development of a chimeric strain of porcine reproductive and respiratory syndrome virus with an infectious clone and a Korean dominant field strain , 2014, Journal of Microbiology.

[27]  Chang-Seon Song,et al.  Development of porcine respiratory and reproductive syndrome virus replicon vector for foot-and-mouth disease vaccine , 2013, Clinical and experimental vaccine research.

[28]  Jaykaran Charan,et al.  How to calculate sample size in animal studies? , 2013, Journal of pharmacology & pharmacotherapeutics.

[29]  T. Pietschmann,et al.  Entry and replication of recombinant hepatitis C viruses in cell culture. , 2013, Methods.

[30]  Xiao-min Wang,et al.  N-Linked Glycosylation of GP5 of Porcine Reproductive and Respiratory Syndrome Virus Is Critically Important for Virus Replication In Vivo , 2012, Journal of Virology.

[31]  M. Beer,et al.  Detection and Typing of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus by Multiplex Real-Time RT-PCR , 2012, PloS one.

[32]  W. Charerntantanakul.  Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects. , 2012, World journal of virology.

[33]  F. Osorio,et al.  Immune Evasion of Porcine Reproductive and Respiratory Syndrome Virus through Glycan Shielding Involves both Glycoprotein 5 as Well as Glycoprotein 3 , 2011, Journal of Virology.

[34]  T. Dokland.  The structural biology of PRRSV , 2010, Virus Research.

[35]  S. Xiao,et al.  Recombination in Vaccine and Circulating Strains of Porcine Reproductive and Respiratory Syndrome Viruses , 2009, Emerging infectious diseases.

[36]  F. Osorio,et al.  The Minor Envelope Glycoproteins GP2a and GP4 of Porcine Reproductive and Respiratory Syndrome Virus Interact with the Receptor CD163 , 2009, Journal of Virology.

[37]  F. Osorio,et al.  Porcine Reproductive and Respiratory Syndrome Virus Nonstructural Protein 1β Modulates Host Innate Immune Response by Antagonizing IRF3 Activation , 2009, Journal of Virology.

[38]  J. Zimmerman,et al.  Detection of Porcine reproductive and respiratory syndrome virus infection in porcine oral fluid samples: a longitudinal study under experimental conditions , 2008, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[39]  I. Díaz,et al.  The challenge of PRRS immunology , 2007, The Veterinary Journal.

[40]  James Kliebenstein,et al.  Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers , 2013, Journal of Swine Health and Production.

[41]  F. Osorio,et al.  Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge. , 2007, Veterinary microbiology.

[42]  F. Osorio,et al.  Protection against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Infection through Passive Transfer of PRRSV-Neutralizing Antibodies Is Dose Dependent , 2007, Clinical and Vaccine Immunology.

[43]  F. Osorio,et al.  Influence of N-Linked Glycosylation of Porcine Reproductive and Respiratory Syndrome Virus GP5 on Virus Infectivity, Antigenicity, and Ability To Induce Neutralizing Antibodies , 2006, Journal of Virology.

[44]  Colin D. Johnson,et al.  Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. , 2005, Journal of the American Veterinary Medical Association.

[45]  Terry Gaasterland,et al.  Computational Principles of Primer Design for Site Directed Mutagenesis , 2005 .

[46]  W. Chittick,et al.  Simultaneous Detection of North American and European Porcine Reproductive and Respiratory Syndrome Virus Using Real-Time Quantitative Reverse Transcriptase–PCR , 2005, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[47]  J. Kwang,et al.  Enhanced replication of porcine reproductive and respiratory syndrome (PRRS) virus in a homogeneous subpopulation of MA-104 cell line , 1993, Archives of Virology.

[48]  F. Osorio,et al.  Gradual development of the interferon-gamma response of swine to porcine reproductive and respiratory syndrome virus infection or vaccination. , 2003, Virology.

[49]  F. Osorio,et al.  Mutations in the genome of porcine reproductive and respiratory syndrome virus responsible for the attenuation phenotype , 2000, Archives of Virology.

[50]  P. Halbur,et al.  Comparison of the Pathogenicity of Two US Porcine Reproductive and Respiratory Syndrome Virus Isolates with that of the Lelystad Virus , 1995, Veterinary pathology.

[51]  S. Dea,et al.  Identification of major differences in the nucleocapsid protein genes of a Québec strain and European strains of porcine reproductive and respiratory syndrome virus. , 1994, The Journal of general virology.